Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics
Source abstract
Abstract
Abstract Proteins are among the most common therapeutics for the treatment of diabetes, autoimmune diseases, cancer, and metabolic diseases, among others. Despite their common use, current protein therapies, most of which are injectables, have several limitations. Large proteins such as monoclonal antibodies (mAbs) suffer from poor absorption after subcutaneous injections, thus forcing their administration by intravenous injections. Even small proteins such as insulin suffer from slow pharmacokinetics which poses limitations in effective management of diabetes. Here, a deep eutectic‐based delivery strategy is used to offer a generalized approach for improving protein absorption after subcutaneous injections. The lead formulation enhances absorption of mAbs after subcutaneous injections by ≈200%. The same composition also improves systemic absorption of subcutaneously injected insulin faster than Humalog, the current gold‐standard of rapid acting insulin. Mechanistic studies reveal that the beneficial effect of deep eutectics on subcutaneous absorption is mediated by their ability to reduce the interactions of proteins with the subcutaneous matrix, especially collagen. Studies also confirm that these deep eutectics are safe for subcutaneous injections. Deep eutectic‐based formulations described here open new possibilities for subcutaneous injections of therapeutic proteins.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Protein purification and stability · Diabetes Management and Research · Diabetes and associated disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
John A. Paulson School of Engineering and Applied Sciences Harvard University 150 Western Ave Allston MA 02134 USA
Wyss Institute for Biologically Inspired Engineering at Harvard University 3 Blackfan St Boston MA 02115 USA
References (50)
Show source-provided references
1. Torre B. G. · Macromol. Chem. · 2021 · 26 · 627
2. 10.1038/d41573-021-00002-010.1038/d41573-021-00002-0 ↗
3. Mullard A. · Nat. Rev. Drug Discovery · 2022 · 21 · 626
4. Jin J. F. · Patient Prefer Adherence · 2015 · 9 · 923
5. Cock E. · PLoS One · 2016 · 1110.1371/journal.pone.0157957 ↗
6. 10.1007/s12325-019-01101-610.1007/s12325-019-01101-6 ↗
7. 10.2147/PPA.S30327910.2147/PPA.S303279 ↗
8. 10.1007/s40271-014-0075-y10.1007/s40271-014-0075-y ↗
9. 10.1182/blood-2020-13654310.1182/blood-2020-136543 ↗
10. 10.1111/cts.1256710.1111/cts.12567 ↗
11. 10.1242/jcs.02382010.1242/jcs.023820 ↗
12. 10.1126/scitranslmed.aaf916610.1126/scitranslmed.aaf9166 ↗
13. 10.1002/psp4.1222410.1002/psp4.12224 ↗
14. 10.2147/IJN.S28341610.2147/IJN.S283416 ↗
15. 10.1056/NEJMoa190786310.1056/NEJMoa1907863 ↗
16. 10.1073/pnas.201090811710.1073/pnas.2010908117 ↗
17. 10.4161/isl.2459010.4161/isl.24590 ↗
18. Noble S. L. · Am. Fam. Physician · 1998 · 57 · 289
19. 10.4161/mabs.4.2.1936410.4161/mabs.4.2.19364 ↗
20. 10.4161/mabs.4.1.1854310.4161/mabs.4.1.18543 ↗
21. 10.1126/scitranslmed.aba667610.1126/scitranslmed.aba6676 ↗
22. 10.1073/pnas.161663911310.1073/pnas.1616639113 ↗
23. 10.1021/bi101926u10.1021/bi101926u ↗
24. 10.1002/adtp.20190009410.1002/adtp.201900094 ↗
25. 10.1021/acs.bioconjchem.6b0065910.1021/acs.bioconjchem.6b00659 ↗
26. 10.1016/j.xphs.2021.11.00810.1016/j.xphs.2021.11.008 ↗
27. 10.1124/dmd.112.04849610.1124/dmd.112.048496 ↗
28. 10.1016/j.xphs.2018.01.00710.1016/j.xphs.2018.01.007 ↗
29. 10.1002/advs.20200481910.1002/advs.202004819 ↗
30. 10.1002/adma.20190110310.1002/adma.201901103 ↗
31. 10.1126/sciadv.abd756310.1126/sciadv.abd7563 ↗
32. 10.1073/pnas.180413911510.1073/pnas.1804139115 ↗
33. 10.1002/adfm.20200291210.1002/adfm.202002912 ↗
34. 10.1016/j.jconrel.2020.07.03710.1016/j.jconrel.2020.07.037 ↗
35. 10.1016/j.jconrel.2018.07.02910.1016/j.jconrel.2018.07.029 ↗
36. 10.1002/adhm.20160141110.1002/adhm.201601411 ↗
37. 10.1073/pnas.211045011910.1073/pnas.2110450119 ↗
38. 10.1016/j.ijpharm.2020.11952310.1016/j.ijpharm.2020.119523 ↗
39. USP 〈790〉 Visible Particulates in Injections United States Pharmacopeia 2022 https://doi.org/10.31003/USPNF_M7197_01_01.10.31003/USPNF_M7197_01_01 ↗
40. 10.1007/s11095-021-03157-y10.1007/s11095-021-03157-y ↗
41. 10.1038/nprot.2011.30510.1038/nprot.2011.305 ↗
42. 10.1517/17460441.2011.53732210.1517/17460441.2011.537322 ↗
43. 10.1002/9780470559277.ch09010210.1002/9780470559277.ch090102 ↗
44. Fischer A. H. · Cold Spring Harb Protoc. · 2008 · 3
45. BALB/C Mouse Hematology Charles River Laboratories 2012 https://www.criver.com/sites/default/files/resources/BALBcMouseClinicalPathologyData.pdf.
46. 10.1016/B978-0-12-803620-4.00017-710.1016/B978-0-12-803620-4.00017-7 ↗
47. Walls R. M. · 2018
48. 10.1002/advs.20210157510.1002/advs.202101575 ↗
49. 10.4158/EP11297.RA10.4158/EP11297.RA ↗
50. E.Lilly Humalog (insulin lispro) injection label [package insert] Food and Drug Administration Eli Lilly 2013 https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020563s115lbl.pdf.